Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249524 | 1.00 | HTR6 (0.38) | HTR6CTSDMTNR1AMTNR1BEPHX2 | |
| SCHEMBL7247168 | 1.00 | HTR6 (0.38) | HTR6CTSDMTNR1AMTNR1BEPHX2 | |
| SCHEMBL7249826 | 0.94 | CYP19A1 (0.41) | HTR6 | |
| SCHEMBL7249821 | 0.94 | CYP19A1 (0.41) | HTR6 | |
| SCHEMBL7246047 | 0.94 | AGER (0.41) | HTR6 | |
| SCHEMBL7249500 | 0.94 | HTR6 (0.36) | HTR6MTNR1AMTNR1B | |
| SCHEMBL7244963 | 0.94 | AGER (0.41) | HTR6MTNR1A | |
| SCHEMBL7244965 | 0.94 | AGER (0.41) | HTR6MTNR1A | |
| SCHEMBL7244072 | 0.94 | AGER (0.41) | HTR6MTNR1A | |
| SCHEMBL7248279 | 0.91 | TAS2R14 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | HTR6 4496/4885CTSD 3167/4885MTNR1A 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.